Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by StrikingMooseon Mar 20, 2018 8:50am

149 Views

Post# 27744936

A message about liver enzymes

Very happy that they pointed out alanine transaminase and aspirate transaminase levels were the same in the test group. Puts all those annoying "well hepatitis gallstone guy who took 600% the dose had increased liver enzymes"

One day I went to my doctor and my ALT level was up 500%. Know what I had to do for treatment? Nothing, because ALT and AST levels aren't even cared about in medicine until they're 10x (even 20x at most times) your normal values.

Just gonna leave this video here too. Will be my background music this morning